• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

After 40 investors rejected Jeff Bezos’ Amazon pitch, his parents offered $245,573 of their retirement savings

2

China now makes up a record 40% of all global container exports—and it’s a sign Trump’s tariffs meant to punish Chinese firms have fallen flat

3

Billionaire Nike cofounder Phil Knight gives $1 billion to his alma mater: ‘This is no time to abandon’ higher education

1

After 40 investors rejected Jeff Bezos’ Amazon pitch, his parents offered $245,573 of their retirement savings

2

China now makes up a record 40% of all global container exports—and it’s a sign Trump’s tariffs meant to punish Chinese firms have fallen flat

3

Billionaire Nike cofounder Phil Knight gives $1 billion to his alma mater: ‘This is no time to abandon’ higher education

Mergers & acquisitions

By
Dan Primack
Dan Primack
Down Arrow Button Icon
By
Dan Primack
Dan Primack
Down Arrow Button Icon
November 29, 2012, 3:22 PM ET
Google source logo
Add Fortune on Google for similar content.

NCR Corp. (NYSE: NCR) has agreed to acquire Retalix Ltd. (Nasdaq: RTLX) for $30 per share (37% premium over Tuesday’s closing price). The deal values Retalix at approximately $650 million.www.retalix.com

Siemens AG has agreed to buy the rail signaling business of Invensys (LSE: ISYS) for $2.9 billion.www.siemens.com

Vivendi SA has received four non-binding offers of more than €6 billion for Brazilian broadband unit GVT SA, according to Reuters. Bidders were: DirecTV, America Movil, Liberty Global and a group of undisclosed private equity firms. Vivendi had been hoping for €7 billion offers, but none have yet arrived.www.vivendi.com

Workshare, a British provider of enterprise collaboration applications, has acquired IdeaPlane, a UK-based enterprise social network for highly-regulated industries. No financial terms were disclosed. www.workshare.com

EQT Partners and GIC next week will begin a €4 billion sale process for German scientific publisherSpringer Science+Business Media, according to Reuters. The firms also are running a parallel process to take Springer public next spring.

Selecta Biosciences Inc., a Watertown, Mass.-based developer of synthetic vaccines and immunotherapies, has entered into a global collaboration with Sanofi (NYSE: SNY) to discover targeted antigen-specific immunotherapies for life-threatening allergies. Under terms of the deal, Selecta could receive up to $300 million in milestone payments, plus up to another $600 million in royalty payments. Selecta has raised over $75 million in VC funding from Rusano, OrbiMed Advisors, Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments. www.selectabio.com

Sign up for Dan’s daily email newsletter on deals and deal-makers: GetTermSheet.com

About the Author
By Dan Primack
See full bioRight Arrow Button Icon

Latest in


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Latest in


    Most Popular

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.